Metabolic Syndrome and Heart Transplantation: An Underestimated Risk Factor?

Autor:	Sponga S; Department of Medicine (DAME), University of Udine, Udine, Italy.; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Vendramin I; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Ferrara V; Department of Medicine (DAME), University of Udine, Udine, Italy., Marinoni M; Department of Medicine (DAME), University of Udine, Udine, Italy., Valdi G; Department of Medicine (DAME), University of Udine, Udine, Italy., Di Nora C; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Nalli C; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Benedetti G; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Piani D; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Lechiancole A; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Parpinel M; Department of Medicine (DAME), University of Udine, Udine, Italy., Bortolotti U; Cardiothoracic Department, University Hospital of Udine, Udine, Italy., Livi U; Department of Medicine (DAME), University of Udine, Udine, Italy.; Cardiothoracic Department, University Hospital of Udine, Udine, Italy.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2024 Mar 08; Vol. 37, pp. 11075. Date of Electronic Publication: 2024 Mar 08 (Print Publication: 2024).
DOI:	10.3389/ti.2024.11075
Abstrakt:	Metabolic Syndrome (MetS), a multifactorial condition that increases the risk of cardio-vascular events, is frequent in Heart-transplant (HTx) candidates and worsens with immunosuppressive therapy. The aim of the study was to analyze the impact of MetS on long-term outcome of HTx patients. Since 2007, 349 HTx patients were enrolled. MetS was diagnosed if patients met revised NCEP-ATP III criteria before HTx, at 1, 5 and 10 years of follow-up. MetS was present in 35% of patients pre-HTx and 47% at 1 year follow-up. Five-year survival in patients with both pre-HTx (65% vs. 78%, p < 0.01) and 1 year follow-up MetS (78% vs 89%, p < 0.01) was worst. At the univariate analysis, risk factors for mortality were pre-HTx MetS (HR 1.86, p < 0.01), hypertension (HR 2.46, p < 0.01), hypertriglyceridemia (HR 1.50, p=0.03), chronic renal failure (HR 2.95, p < 0.01), MetS and diabetes at 1 year follow-up (HR 2.00, p < 0.01; HR 2.02, p < 0.01, respectively). MetS at 1 year follow-up determined a higher risk to develop Coronary allograft vasculopathy at 5 and 10 year follow-up (25% vs 14% and 44% vs 25%, p < 0.01). MetS is an important risk factor for both mortality and morbidity post-HTx, suggesting the need for a strict monitoring of metabolic disorders with a careful nutritional follow-up in HTx patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Sponga, Vendramin, Ferrara, Marinoni, Valdi, Di Nora, Nalli, Benedetti, Piani, Lechiancole, Parpinel, Bortolotti and Livi.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu